Dr Lionel Hebbard

Senior Research Fellow
Medicine, Westmead Clinical School
The Westmead Institute for Medical Research

Member of the Charles Perkins Centre

Telephone (612) 86273533

Website Related website
Related website

Map

Biographical details

Dr Lionel Hebbard is a scientist, employed as a Senior Research Fellow in the Sydney Medical School and the Storr Liver Unit, Westmead Millennium Institute. He completed his PhD in Germany and for his postdoctoral time he worked at the University Hospital Zurich, Switzerland and the Burnham Institute for Medical Research, La Jolla, USA. He returned from the USA in 2008 to continue his research in Australia. His current research focuses on the role of adiponectin and its receptors in cancer, liver injury and fibrosis and metabolism.

His current work employs a combination of mouse models, molecular biology, cell biology and histology. The work will be based in the Storr Liver Unit which has the advantage of being able to draw on patient data and samples to further support experimental data. Dr Hebbard completed his PhD in 1999 at the Institute for Genetics, Forschungszentrum Karlsruhe, Germany. His doctoral studies dealt with the role of CD44 in mouse and rat mammary gland development (J Cell Sci.,113, 2619-30; 2000). In his first Postdoctoral position at the University Hospital Zurich, Switzerland under Professor Roman Klemenz, he was part of the team who found T-cadherin to be upregulated on the vasculature of mouse tumours (Cancer Research, 60, 4682-4688, 200). In 2001 he moved to the Burnham Institute of Medical Research in La Jolla, California, to continue his work with Professor Barbara Ranscht. There Dr Hebbard characterized the function of T-cadherin in angiogenesis and mammary cancer (Cancer Research, 64, 169-179, 2004). He characterized knock-out T-cadherin mice and created transgenic mice and used them to functionally determine that the interaction of adiponectin and T-cadherin is an important mediator of angiogenesis and mammary tumour growth and progression (Cancer Res 68, 1407-16, 2008, Clin Cancer Res, 2009;15:3256-3264). To learn about cancer stem cells Dr Hebbard worked with Professor Robert Oshima at the Burnham Institute from February 2007 to May 2008. There, using mouse models he tested new chemical inhibitors (Oncogene 2011, 30(3):301-12) and elucidated the role of MELK (mammalian embryonic leucine kinase) in mouse mammary mammary models (Cancer Res 2010;70:8863-8873).

Research interests

Doctor Hebbard is a PhD scientist with a passionate interest in cancer biology, stem cells, tumour metabolism and in tissue responses to injury.

Teaching and supervision

Pathology of Cancer

Tumour metabolism

Current projects

1. Role of metabolism in liver cancer stem cells and tumour progression

2. Targeting liver fibrosis

3. Understanding tissue cross-talk in hepatic disease

Associations

Gastroenterological Society of Australia (GESA)

European Society for the study of the Liver (EASL)

Awards and honours

Fellowship from the Royal Australian College of Physicians for MPhil studies (1992-3)

PhD Fellowship for doctoral work from the Forschungszentrum Karlsruhe, Germany (1995-99)

Travel fellowship from the Keystone Conference Foundation (2004)

Career development award from the Fishman Fund (2005)

NSW Cancer Council Innovation Grant (2011)

WMI Science prize 2013

NSW Cancer Council Project Grant 2014-6

In the media

https://au.lifestyle.yahoo.com/prevention/health/article/-/23299705/obesity-linked-to-liver-cancer/

http://www.parracity.nsw.gov.au/your_council/news/media/2014/may_2014/a_toast_to_the_biggest_morning_tea

http://www.news.com.au/lifestyle/health/sydney-university-study-finds-cholesterol-spreads-cancer-in-body/story-fneuz9ev-1226907900782

http://www.cancercouncil.com.au/wp-content/uploads/2014/06/CC-June-2014-Newsletter-26-v43-050614-web-.pdf

International links

Belgium

(University Leuven) Professor Tania Roskams

United States

(Burnham Institute of Medical Research) Professor Barbara Ranscht Professor Robert Oshima

Selected grants

2015

  • Exploiting the pharmacokinetic and pharmacodynamic properties of bile acid receptor agonists to treat liver disease; Liddle C, Hebbard L, Downes M; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Metabolic drivers of liver cancer progression; Hebbard L, Qiao L; Cancer Council New South Wales/Research Project Grants.
  • Novel approaches to target cancer stem cells in liver cancer; Liddle C, Qiao L, Duan W, Hebbard L; Cancer Council New South Wales/Research Project Grants.

2013

  • Adiponectin and cholesterol a driving force in NASH immunopathogenesis; George J, Hebbard L, Bendall L; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Small Rodent Airlaw Caging System; George J, O'Connell P, Cunningham A, Hawthorne W, Little D, Djordjevic J, Harris D, Hebbard L, Liddle C, Fletcher J; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • Objective Measurement of Physical Activity and Sedentary Behaviou; Baur L, George J, Cunningham A, Djordjevic J, Fletcher J, Harris D, Hawthorne W, Hebbard L, Liddle C, Little D, O'Connell P; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • The BD Influx High Speed Cell Sorter; Cunningham A, George J, Rizos H, Clarke C, Reddel R, Kefford R, North K, Stewart G, Jones C, Tam P, Alexander S, Gottlieb D, Bradstock K, Bryan T, Booth D, Bendall L, Brilot-Turville F, Hebbard L, Cooper S, Wang Y, Wang X; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Novel molecular targets for treatment of hepatocellular cancer (HCC); Hebbard L, George J; Cancer Council New South Wales/Innovator Grant.
  • Role of adiponectin in hepatic carcinogenesis; George J, Hebbard L; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • The role of adiponectin receptors in liver fibrosis formation; George J, Hebbard L; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The BD Influx High Speed Cell Sorter; Kefford R, Cunningham A, Bendall L, Clarke C, Harris D, Alexander S, Tam P, Sorrell T, Iredell J, Bryan T, Rizos H, Wang Y, Hebbard L; National Health and Medical Research Council (NHMRC)/Equipment Grants.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]
  • Hebbard, L. (2012). Role of Angiogenesis in HCC Development and Therapy. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 149-161). Sharjah: Bentham Science Publishers. [More Information]

Journals

  • Alzahrani, B., Iseli, T., Ramezani-Moghadam, M., Ho, V., Wankell, M., Sun, E., Qiao, L., George, J., Hebbard, L. (2018). The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics, 1864 (3), 700-708. [More Information]
  • Obeid, S., Wankell, M., Charrez, B., Sternberg, J., Kreuter, R., Esmaili, S., Ramezani-Moghadam, M., Devine, C., Read, S., Bhathal, P., Ahlenstiel, G., Qiao, L., George, J., Hebbard, L., et al (2017). Adiponectin confers protection from acute colitis and restricts a B cell immune response. Journal of Biological Chemistry, 292(16), 6569-6582. [More Information]
  • Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2017). Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics, 7(16), 3948-3961. [More Information]
  • Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Qiao, L., George, J., Hebbard, L. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, disease progression, and liver cancer stem cells. Molecular Cancer, 16(1), 1-10. [More Information]
  • Dewdney, B., Hebbard, L. (2017). Implementing genetic screening for the management of hepatic disease. Hepatobiliary Surgery and Nutrition, 6(5), 359-362. [More Information]
  • Wu, G., Wilson, G., George, J., Liddle, C., Hebbard, L., Qiao, L. (2017). Overcoming treatment resistance in cancer: Current understanding and tactics. Cancer Letters, 387, 69-76. [More Information]
  • Han, S., Latchoumanin, O., Wu, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2017). Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters, 390, 188-200. [More Information]
  • Charrez, B., Qiao, L., Hebbard, L. (2016). Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. World Journal of Gastroenterology, 22(8), 2494-2502. [More Information]
  • Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T., Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 290(9), 5533-5542. [More Information]
  • Wilson, G., Hebbard, L., Duan, W., Qiao, L., George, J. (2015). Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. Current Gene Therapy, 15(2), 93-96.
  • Wilson, G., Hebbard, L., Duan, W., George, J., Qiao, L. (2015). Editorial: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications. Current Stem Cell Research & Therapy, 10(3), 190-192.
  • Heeboll, S., Thomsen, K., Clouston, A., Sundelin, E., Radko, Y., Christensen, L., Ramezani-Moghadam, M., Kreutzfeldt, M., Pedersen, S., Jessen, N., Hebbard, L., George, J., et al (2015). Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research, 95-96, 34-41. [More Information]
  • Wu, G., Wilson, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2015). Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. Discovery Medicine, 20(110), 219-229.
  • Charrez, B., Qiao, L., Hebbard, L. (2015). The role of fructose in metabolism and cancer. Hormone Molecular Biology and Clinical Investigation, 22(2), 79-89. [More Information]
  • Dai, Y., Jiao, H., Teng, G., Wang, W., Zhang, R., Wang, Y., Hebbard, L., George, J., Qiao, L. (2014). Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. Molecular Cancer Therapeutics, 13(5), 1206-1216. [More Information]
  • Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
  • Hebbard, L., Ranscht, B. (2014). Multifaceted roles of adiponectin in cancer. Best Practice and Research: Clinical Endocrinology and Metabolism, 28(1), 59-69. [More Information]
  • Jiang, C., Pu, C., Hou, Y., Chen, Z., Alanazy, M., Hebbard, L. (2014). Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World Journal of Gastroenterology, 20(44), 16464-16473. [More Information]
  • Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., Grønbæk, H. (2014). Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International, 34(10), 1584-1592. [More Information]
  • Alzahrani, B., Iseli, T., Hebbard, L. (2014). Non-viral causes of liver cancer: does obesity led inflammation play a role? Cancer Letters, 345(2), 223-229. [More Information]
  • Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014). Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters, 351(2), 232-241. [More Information]
  • Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Castro, D., Maurer, J., Hebbard, L., Oshima, R. (2013). ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell. Stem Cells, 31(1), 12-22. [More Information]
  • Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]
  • Obeid, S., Hebbard, L. (2012). Role of Adiponectin and Its Receptors in Cancer. Cancer Biology & Medicine, 9, 213-220. [More Information]
  • Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
  • Hebbard, L., Cecena, G., Golas, J., Sawada, J., Ellies, L., Charbono, A., Williams, R., Jimenez, R., Wankell, M., et al (2011). Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene, 30(3), 301-312. [More Information]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PloS One, 5(9), 1-10. [More Information]
  • Hebbard, L., Maurer, J., Miller, A., Lesperance, J., Hassell, J., Oshima, R., Terskikh, A. (2010). MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo. Cancer Research, 70(21), 8863-8873. [More Information]
  • Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]
  • Denzel, M., Hebbard, L., Shostak, G., Shapiro, L., Cardiff, R., Ranscht, B. (2009). Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clinical Cancer Research, 15(10), 3256-3264. [More Information]
  • Hebbard, L., Garlatti, M., Young, L., Cardiff, R., Oshima, R., Ranscht, B. (2008). T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Research, 68(5), 1407-1416. [More Information]
  • Oshima, R., Lesperance, J., Munoz, V., Hebbard, L., Ranscht, B., Sharan, N., Muller, W., Hauser, C., Cardiff, R. (2004). Angiogenic Acceleration of Neu induced mammary tumor progression and metastasis. Cancer Research, 64(1), 169-179. [More Information]
  • Hebbard, L., Steffen, A., Zawadzki, V., Fieber, C., Howells, N., Moll, J., Ponta, H., Hofmann, M., Sleeman, J. (2000). CD44 expression and regulation during mammary gland development and function. Journal of Cell Science, 113(14), 2619-2630.
  • Wyder, L., Vitaliti, A., Schneider, H., Hebbard, L., Moritz, D., Wittmer, M., Ajmo, M., Klemenz, R. (2000). Increased Expression of H/T-Cadherin in Tumor-penetrating Blood Vessels. Cancer Research, 60(17), 4682-4688.

2018

  • Alzahrani, B., Iseli, T., Ramezani-Moghadam, M., Ho, V., Wankell, M., Sun, E., Qiao, L., George, J., Hebbard, L. (2018). The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics, 1864 (3), 700-708. [More Information]

2017

  • Obeid, S., Wankell, M., Charrez, B., Sternberg, J., Kreuter, R., Esmaili, S., Ramezani-Moghadam, M., Devine, C., Read, S., Bhathal, P., Ahlenstiel, G., Qiao, L., George, J., Hebbard, L., et al (2017). Adiponectin confers protection from acute colitis and restricts a B cell immune response. Journal of Biological Chemistry, 292(16), 6569-6582. [More Information]
  • Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2017). Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics, 7(16), 3948-3961. [More Information]
  • Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Qiao, L., George, J., Hebbard, L. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, disease progression, and liver cancer stem cells. Molecular Cancer, 16(1), 1-10. [More Information]
  • Dewdney, B., Hebbard, L. (2017). Implementing genetic screening for the management of hepatic disease. Hepatobiliary Surgery and Nutrition, 6(5), 359-362. [More Information]
  • Wu, G., Wilson, G., George, J., Liddle, C., Hebbard, L., Qiao, L. (2017). Overcoming treatment resistance in cancer: Current understanding and tactics. Cancer Letters, 387, 69-76. [More Information]
  • Han, S., Latchoumanin, O., Wu, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2017). Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters, 390, 188-200. [More Information]

2016

  • Charrez, B., Qiao, L., Hebbard, L. (2016). Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. World Journal of Gastroenterology, 22(8), 2494-2502. [More Information]

2015

  • Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T., Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 290(9), 5533-5542. [More Information]
  • Wilson, G., Hebbard, L., Duan, W., Qiao, L., George, J. (2015). Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. Current Gene Therapy, 15(2), 93-96.
  • Wilson, G., Hebbard, L., Duan, W., George, J., Qiao, L. (2015). Editorial: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications. Current Stem Cell Research & Therapy, 10(3), 190-192.
  • Heeboll, S., Thomsen, K., Clouston, A., Sundelin, E., Radko, Y., Christensen, L., Ramezani-Moghadam, M., Kreutzfeldt, M., Pedersen, S., Jessen, N., Hebbard, L., George, J., et al (2015). Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research, 95-96, 34-41. [More Information]
  • Wu, G., Wilson, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2015). Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. Discovery Medicine, 20(110), 219-229.
  • Charrez, B., Qiao, L., Hebbard, L. (2015). The role of fructose in metabolism and cancer. Hormone Molecular Biology and Clinical Investigation, 22(2), 79-89. [More Information]

2014

  • Dai, Y., Jiao, H., Teng, G., Wang, W., Zhang, R., Wang, Y., Hebbard, L., George, J., Qiao, L. (2014). Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. Molecular Cancer Therapeutics, 13(5), 1206-1216. [More Information]
  • Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
  • Hebbard, L., Ranscht, B. (2014). Multifaceted roles of adiponectin in cancer. Best Practice and Research: Clinical Endocrinology and Metabolism, 28(1), 59-69. [More Information]
  • Jiang, C., Pu, C., Hou, Y., Chen, Z., Alanazy, M., Hebbard, L. (2014). Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World Journal of Gastroenterology, 20(44), 16464-16473. [More Information]
  • Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., Grønbæk, H. (2014). Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International, 34(10), 1584-1592. [More Information]
  • Alzahrani, B., Iseli, T., Hebbard, L. (2014). Non-viral causes of liver cancer: does obesity led inflammation play a role? Cancer Letters, 345(2), 223-229. [More Information]
  • Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014). Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters, 351(2), 232-241. [More Information]

2013

  • Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
  • Castro, D., Maurer, J., Hebbard, L., Oshima, R. (2013). ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell. Stem Cells, 31(1), 12-22. [More Information]
  • Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]

2012

  • Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]
  • Obeid, S., Hebbard, L. (2012). Role of Adiponectin and Its Receptors in Cancer. Cancer Biology & Medicine, 9, 213-220. [More Information]
  • Hebbard, L. (2012). Role of Angiogenesis in HCC Development and Therapy. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 149-161). Sharjah: Bentham Science Publishers. [More Information]

2011

  • Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
  • Hebbard, L., Cecena, G., Golas, J., Sawada, J., Ellies, L., Charbono, A., Williams, R., Jimenez, R., Wankell, M., et al (2011). Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene, 30(3), 301-312. [More Information]

2010

  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PloS One, 5(9), 1-10. [More Information]
  • Hebbard, L., Maurer, J., Miller, A., Lesperance, J., Hassell, J., Oshima, R., Terskikh, A. (2010). MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo. Cancer Research, 70(21), 8863-8873. [More Information]
  • Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]

2009

  • Denzel, M., Hebbard, L., Shostak, G., Shapiro, L., Cardiff, R., Ranscht, B. (2009). Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clinical Cancer Research, 15(10), 3256-3264. [More Information]

2008

  • Hebbard, L., Garlatti, M., Young, L., Cardiff, R., Oshima, R., Ranscht, B. (2008). T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Research, 68(5), 1407-1416. [More Information]

2004

  • Oshima, R., Lesperance, J., Munoz, V., Hebbard, L., Ranscht, B., Sharan, N., Muller, W., Hauser, C., Cardiff, R. (2004). Angiogenic Acceleration of Neu induced mammary tumor progression and metastasis. Cancer Research, 64(1), 169-179. [More Information]

2000

  • Hebbard, L., Steffen, A., Zawadzki, V., Fieber, C., Howells, N., Moll, J., Ponta, H., Hofmann, M., Sleeman, J. (2000). CD44 expression and regulation during mammary gland development and function. Journal of Cell Science, 113(14), 2619-2630.
  • Wyder, L., Vitaliti, A., Schneider, H., Hebbard, L., Moritz, D., Wittmer, M., Ajmo, M., Klemenz, R. (2000). Increased Expression of H/T-Cadherin in Tumor-penetrating Blood Vessels. Cancer Research, 60(17), 4682-4688.

To update your profile click here. For support on your academic profile contact .